ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 394
- Registration Number
- NCT04758117
- Locations
- 🇨🇦
Dr. Jonathan D. Chan Inc. /ID# 241611, Vancouver, British Columbia, Canada
🇨🇦Dr Naik-Medical Professional Corporation-Alliance Health /ID# 234149, Saskatoon, Saskatchewan, Canada
🇩🇪Rheumahaus Studien GbR, Potsdam, DE /ID# 230771, Potsdam, Brandenburg, Germany
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 118
- Registration Number
- NCT04750226
- Locations
- 🇺🇸
University of South Alabama /ID# 218467, Mobile, Alabama, United States
🇺🇸Thomas Jefferson University Hospital /ID# 218594, Philadelphia, Pennsylvania, United States
🇺🇸Visionary Investigators Network - Miami /ID# 217726, Miami, Florida, United States
A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
- Conditions
- Pyoderma Gangrenosum
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT04750213
- Locations
- 🇯🇵
Kumamoto University Hospital /ID# 244050, Kumamoto shi, Kumamoto, Japan
🇯🇵Okinawa Kyodo Hospital /ID# 241739, 那覇市, Okinawa, Japan
🇯🇵Japanese Red Cross Osaka Hospital /ID# 228782, Osaka-shi, Osaka, Japan
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
- Conditions
- Advanced Solid Tumors CancerNon Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 81
- Registration Number
- NCT04721015
- Locations
- 🇯🇵
Duplicate_National Hospital Organization Shikoku Cancer Center /ID# 240821, Matsuyama-shi, Ehime, Japan
🇺🇸Dana-Farber Cancer Institute /ID# 231209, Boston, Massachusetts, United States
🇺🇸Washington University-School of Medicine /ID# 225698, Saint Louis, Missouri, United States
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma (MM)
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 514
- Registration Number
- NCT04721002
- Locations
- 🇭🇷
Klinicki bolnicki centar Zagreb /ID# 226969, Zagreb, Grad Zagreb, Croatia
🇨🇿Fakultni nemocnice Hradec Kralove /ID# 224089, Hradec Kralove, Czechia
🇫🇷AP-HP - Hopital Necker /ID# 228062, Paris, France
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 174
- Registration Number
- NCT04713592
- Locations
- 🇺🇸
Menter Dermatology Res Inst /ID# 219161, Dallas, Texas, United States
🇺🇸Medderm Associates /ID# 219210, San Diego, California, United States
🇺🇸Dawes Fretzin, LLC /ID# 219219, Indianapolis, Indiana, United States
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- Conditions
- AMDnAMDWet Age-related Macular DegenerationNeovascular AMDwAMDWet AMDCNVNeovascular Age-related Macular DegenerationChoroidal Neovascularization
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 540
- Registration Number
- NCT04704921
- Locations
- 🇺🇸
170-Barnet Dulaney Perkins Eye Center, Sun City, Arizona, United States
🇺🇸188-Colorado Retina Associates (CRA) - Red Rocks Medical Center Location, Lakewood, Colorado, United States
🇺🇸291-The Retina Institute, Saint Louis, Missouri, United States
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 105
- Registration Number
- NCT04686786
- Locations
- 🇺🇸
Little Rock, Arkansas, Little Rock, Arkansas, United States
🇺🇸Jacksonville, Florida, Jacksonville, Florida, United States
🇺🇸Lexington, Kentucky, Lexington, Kentucky, United States
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
- Conditions
- Episodic MigraineChronic Migraine
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 596
- Registration Number
- NCT04686136
- Locations
- 🇺🇸
Mount Vernon Clinical Research /ID# 226249, Chattanooga, Tennessee, United States
🇩🇪Neuropoint GmbH /ID# 226313, Ulm, Germany
🇨🇦Ottawa Headache Centre Research Inc /ID# 226451, Ottawa, Ontario, Canada
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04666675